These Analysts Boost Their Forecasts On Silence Therapeutics After Full Year 2023 Results
Portfolio Pulse from Avi Kapoor
Silence Therapeutics Plc (NASDAQ:SLN) reported a narrower loss for 2023 compared to the previous year, with increased collaboration revenues and a significant boost in cash position. Analysts from Chardan Capital and Morgan Stanley raised their price targets on SLN following these results and the announcement of positive data from the ALPACAR-360 phase 2 study.
March 14, 2024 | 6:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silence Therapeutics reported a narrower loss for 2023, increased collaboration revenues, and a significant cash position boost. Analysts from Chardan Capital and Morgan Stanley raised their price targets on SLN.
The positive financial results and the raised price targets by analysts from Chardan Capital and Morgan Stanley indicate a strong performance and outlook for Silence Therapeutics. The narrower loss, increased revenues, and substantial cash position are likely to instill investor confidence, potentially leading to a short-term positive impact on SLN's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100